HSCS HeartSciences Inc.

$2.06

HeartSciences Inc. (HSCS) is expected to report earnings on October 22, 2026, after the market close. The consensus earnings estimate is a loss of $0.78 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.6% since its last earnings release on July 23, 2026.

HeartSciences Missed Consensus Estimates
Thursday, July 23, 2026 · 5:15 PM ET
Earnings Date
1st Quarter, Jul 2026
Oct 22
Thursday · 5:15 PM ET
Earnings Whisper
-
vs ($0.78)
Rev est $100K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.14

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About HeartSciences Inc.

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction.

Sector

Healthcare

Industry

Medical Instruments/Supply